1. A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non– Small-Cell Lung Cancer 
Benjamin Levy, MD, Alexander Spira, MD, Daniel Becker, MD, Tracey Evans, MD, Ian Schnadig, MD, D. Ross Camidge, MD, PhD, Julie E. Bauman, Diana Hausman, MD, Luke Walker, MD, John Nemunaitis, MD, Charles M. Rudin, MD, PhD, Balazs Halmos, MD, Daniel W. Bowles, MD 
Journal of Thoracic Oncology 
Volume 9, Issue 7, Pages (July 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
CONSORT diagram showing the progress of patients though the trial, adapted from Begg et al, Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637–639.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan–Meier curves for progression-free survival (days). NSCLC, non–small-cell lung cancer.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4. FIGURE 3
Kaplan–Meier curves for overall survival (days). NSCLC, non–small-cell lung cancer.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions